1706738-98-8
1706738-98-8
Chemical Structure
Trotabresib
Synonym(s): CC-90010
- CAS No.: 1706738-98-8
- Formula:C21H21NO4S
- Molecular Weight:383.46
IUPAC Name: 4-(2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl)-2-methylisoquinolin-1(2H)-one
InChIKey: UWZAJPITKGWMFJ-UHFFFAOYSA-N
SMILES: O=C1N(C)C=C(C2=CC(S(=O)(C)=O)=CC=C2OCC3CC3)C4=C1C=CC=C4
Biological Activity: CC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Trotabresib | 99.74% | CC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. CELGENE QUANTICEL RESEARCH, INC. PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR. Patent. WO2020023438.
- [2]. V. Moreno, et al. CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study.
Keywords
